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Spinal muscular atrophy (SMA) is the most common lethal recessive disease in childhood, and there is currently no
effective treatment to halt disease progression. The translation of scientific advances into effective therapies is
hampered by major roadblocks in clinical trials, including the complex regulatory environment in Europe, variations
in standards of care, patient ascertainment and enrolment, a narrow therapeutic window and a lack of biomarkers
of efficacy. In this context, SMA-Europe organized its first international workshop in July 2012 in Rome, gathering 34
scientists, clinicians and representatives of patient organizations to establish recommendations for improving
clinical trials for SMAa.
Keywords: Spinal muscular atrophy, Clinical trials, Preclinical drug selection, Phase III trial planning, Patient
registries, Neonatal trials, Newborn screening, Standards of care, European regulations, Efficacy biomarkersCorrespondence
SMA is caused by homozygous absence of the SMN1
gene and retention of the SMN2 gene [1] resulting in
degeneration of spinal motoneurons. The phenotypic
spectrum ranges from severe (Type I) to mild (Type III,
IV). To date, 26 SMA clinical trials of 12 different drugs
have failed to show any significant effect on disease pro-
gression [2].
Analyses of past clinical trials show issues in the drug
selection process and the study design. Drug selection
based on preclinical data obtained from transformed cell
lines may not be a reliable predictor of a therapeutic ef-
fect in motoneurons. The majority of Phase I and II tri-
als have used patients with Types II and III SMA and
Phase III trial design is underdeveloped.
Trial implementation in Europe faces specific chal-
lenges. Information on the SMA population is fragmen-
tary, reliable natural history data is lacking and the
degree of variation in incidence and survival between
countries is unknown. SOC vary from center to center [3]
making the creation of homogeneous trial populations* Correspondence: kayadjanian@gmail.com
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distribution, and reproduction in any mediumdifficult. The lack of a homogeneous regulatory frame-
work between individual European member States leads
to delays and increased costs.
SMA Type I is estimated to constitute 60% of the total
incident SMA population with SMA Types II and III
comprising 30% and 10% respectively [4]. Analyses of
patient registries (Table 1) show that SMA Type I is un-
derrepresented, suggesting that a significant proportion
of SMA cases go unrecorded. Given the short life ex-
pectancy of SMA Type I patients and the narrow thera-
peutic time-window, it is vital to reduce the age of
diagnosis and time for recording into registry.
Treatment in late-stage of the disease could partly ex-
plain past trial failures. Mouse studies show that neo-
natal treatment is probably critical for efficacy [5-7].
Clinical studies (Carnival-Type I, STOPSMA) suggest
that the first few months of life are the most critical
times of denervation in SMA Types I and II. These find-
ings support the implementation of neonatal trials and
the development of strategies for identifying patients at
pre-symptomatic or early-symptomatic stages.
Several arguments support newborn screening (NBS)
for SMA despite the lack of treatmentb. SMA is an early
onset, often fatal disease with a well-understood molecularntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 SMA patient registries
Database information Families of SMA International IU FSMA Registry MDA Treat-NMD Estimated
Number of patients 11,000 3,000 5,500 2,400
SMA subtypes (%) I* 51 I 28 I 19.1 I 20 I 60
II* 24 II 33.5 II 35.4 II 43 II 30
III* 12 III 26 III 28.8 III 37 III 10
IV/Unknown* 13 IV 16.7
Average age of diagnosis (months) I 4.9
II 18.7
Average age at entry into registry (months) I 6
II 20
*Calculated from approximately 1,000 newly diagnosed patients contacting FSMA over the previous three-year period (Courtesy of Families of SMA).
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significantly the lifespan of SMA patients, especially for
SMA Type I [8]. Treatment at the neonatal stage could be
effective. Advances in genomic technologies now make
NBS feasible. While pilot studies exploring NBS for SMA
are underway in the US, discussion about implementing
NBS in Europe is in its infancy.
Several issues should be considered before conducting
clinical trials in neonates. A key concern is to define
whether the use of placebo controls or natural history
data should be preferred in clinical trials. Natural history
data in the immediate postnatal period is lacking. An-
other challenge is the absence of validated markers of
disease progression. For SMA Type I, electrophysio-
logical measures such as MUNE and CMAP may be bet-
ter indicators of efficacy than survival [9]. Biomarkers
like ventilatory function and muscle mass quantification
should be explored during the postnatal period. Treat-
ment of pre-symptomatic infants also raises ethical is-
sues. In determining trial duration, efficacy should be
balanced with the costs and family burden. Finally, the
feasibility of establishing consensus guidelines for SOC
for neonates should be explored. In parallel, the effect of
SOC on improving survival and on the therapeutic win-
dow should be assessed.
Biomarkers of treatment effects which are clinically
meaningful and sensitive to disease changes within the
time-frame of trials are urgently needed. Currently, nu-
merous overlapping motor functional scales serve as
clinical end-points. Although ongoing Rasch analysesc
should help to create less redundant and more robust
scales, the field would benefit from developing scales
that are multifactorial, linear, clinically relevant and sen-
sitive to clinical change. These should be adapted for pre-
symptomatic, early-symptomatic and chronic stages for
each SMA subtype. Consistent with most therapeutic ap-
proaches intended to increase SMN levels, efforts to de-
velop surrogate markers have focused on measuring SMNexpression in blood. Whether this reflects what is happen-
ing in relevant nervous system tissues remains uncertain,
other biomarkers need to be testedd or developed.
Summary of recommendations
1. The preclinical effectiveness of therapeutics should
be tested in SMA animal models.
2. Plan the feasibility of ensuing phase I, II and III
clinical trials.
3. Harmonization of the European regulatory process
for drug approval should be strongly advocated.
4. Methods should be developed to either ensure
patients are drawn from populations with uniform
SOC or for integrating populations with different
SOC within one clinical trial.
5. The optimal therapeutic window should be targeted
in SMA clinical trials by:
Reducing age at enrollment into clinical trials.
Advancing early diagnosis (NBS).
Reducing time for entry into registry.
Enrolling pre-symptomatic siblings.




Study natural history of the early postnatal period.
Develop new biomarkers.
7. Biomarkers
Develop measures of upper limb function for non-
ambulant patients.
Explore muscle biomarkers (MUNE/CMAP,
muscle MRI, EIM).
Test the SMA Foundation’s biomarker paneld.
Endnotes
aMore information can be found on the SMA-EUROPE
website.
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by Wilson and Jungner in 1968. With the advances of
genetic technology over the past forty years, the original
ten principles laid out by Wilson and Jungner have been
revised [10]. For example, the criterion “treatment avail-
able” is often broadened in many discussions to include
broader health benefits and other advantages to parents,
especially avoiding a diagnostic odyssey and informed
reproductive choice [11].
cRasch analysis is supported by the patient advocacy
group of the International Coordinating Committee
for SMA clinical trials which includes families of SMA,
Fight SMA, MDA , the SMA Foundation and SMA-
Europe.
dAs a result of the BforSMA study discovery effort, a
panel of 27 validated plasma protein biomarkers was
created by Myriad RBM in collaboration with the SMA
Foundation. The SMA-MAP panel is available at Myriad
RBM.
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